Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Name: Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
Published: 2017
License: Public Domain

AbbVie · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

asian cirrhosis co-infection human-immunodeficiency-virus interferon

hepatitis c virus (hcv), chronic hepatitis c virus (hcv), genotype 1 to 6, cirrhosis, compensated cirrhosis, human immunodeficiency virus, co-infection, treatment-naïve, treatment-experienced, interferon, asian, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Related documents